From May 26th, Yantai City will participate in public medical institutions, military medical institutions and medical insurance in the centralized procurement of insulin by national medical insurance. The designated private medical institutions will fully implement the results of the centralized procurement of insulin with quantity, and the majority of diabetic patients will be able to purchase insulin products with “high quality and reasonable price”.
Insulin is an important drug for diabetic patients to control blood sugar and has an irreplaceable position in the treatment of diabetes. This special centralized procurement of insulin is the first time that the country has expanded the centralized procurement of drugs to the field of biological drugs. A total of 16 generic varieties were selected, involving 42 products from 11 companies, covering commonly used clinical second- and third-generation insulins, including Meal human insulin, basal human insulin, premixed human insulin, prandial insulin analogs, basal insulin analogs, and premixed insulin analogs are divided into six categories. The price of the selected products dropped by an average of 48%, and Lilly’s protamine zinc recombinant insulin lispro mixture (25R) dropped the most, which was close to 73%. /strong>Take the commonly used clinical insulin glargine as an example, from an average of 180 yuan per injection to about 70 yuan per injection, each patient can save about 4,000 yuan per year. A total of 354 medical institutions in Yantai City participated in the report, and the agreed purchase volume in the first year was about 2.26 million per bottle, which can save patients more than 60 million yuan in medical expenses every year.
This centralized procurement has optimized the procurement rules for the characteristics of insulin.
One is to fully respect the clinical choice, maintain the stability of clinical medication, and reduce the risk of substitution.
The second is the merger and competition of different generic insulins with the same therapeutic purpose and clinical mechanism of action, taking into account the needs of clinical use and the sufficiency of the competition.
The third is to attach great importance to the supply of selected products. This centralized procurement with volume has certain requirements on the production capacity of pharmaceutical companies, that is, the agreed procurement volume of the selected companies shall not exceed 50% of the company’s maximum production capacity to ensure sufficient production capacity of the selected companies.
The Yantai Municipal Medical Insurance Bureau kindly reminds the majority of patients that after the successful outcome of the centralized insulin procurement with the quantity, diabetic patients can purchase and use the selected insulin at the relevant designated medical institutions to control their blood sugar and maintain good health. lifestyle. In the next step, the Municipal Medical Insurance Bureau will continue to expand the scope and improve the quality of the implementation of the results of the centralized procurement with quantity, so as to bring more “high-quality and affordable” centralized procurement products for patients.
Source: Yantai Medical Security Bureau